Aclaris announces phase 2 clinical trial of ATI-502 topical did not meet endpoints
Aclaris announced results from a Phase 2 clinical trial of ATI-502 (AA-201 Topical), an investigational topical Janus Kinase 1/3 inhibitor, in patients with alopecia areata. ATI-502 did not achieve statistical superiority at the primary or secondary endpoints. June 26, 2019